Lipoprotein Metabolism and Bacterial Lipopolysaccharide in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-03

Study Completion Date

2017-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with Parkinson's disease (PD) present an impaired intestinal permeability with consequent lipopolysaccharide (LPS) translocation in the systemic circulation. Plasmatic lipoproteins play a key role in the detoxification of LPS.

The investigators aim to study the relationships between lipoprotein chemical composition and plasma LPS circulation in PD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of a Lipidic and Proteic Controlled Diet on Parkinson's Disease

NCT02687698

Parkinson Disease

UNKNOWN NA

Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease

NCT01155492

Parkinson's Disease Multiple System Atrophy

COMPLETED

Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease

NCT01904240

Parkinson's Disease

COMPLETED

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

NCT03230526

Parkinson Disease

ACTIVE_NOT_RECRUITING PHASE2

Electroencephalographic Signatures of Neuropsychiatric Fluctuations in Parkinson's Disease

NCT06301282

Parkinson Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bacterial lipopolysaccharides are able to produce neuroinflammation and dopaminergic receptors degeneration. In addition, they may produce an accumulation of α-synuclein in the area of the substantia Nigra. Recent studies have shown that α-synuclein aggregates may be present also in gastrointestinal neurons of patients with PD. This last finding led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. Forsyth et al. have discovered an impaired intestinal permeability in subjects with recently diagnosed PD, and they found positive correlations between this factor, exposure to LPS and alpha-synuclein accumulation in gastrointestinal neurons. Plasma lipoproteins play a key role in the detoxification of bacterial endotoxins. Lipoprotein chemical composition is related to their detoxing properties. To the best of investigator knowledge, the relationships between lipoprotein chemical composition and LPS in PD have not yet been investigated. Therefore, the aims of this study are: I) to evaluate the chemical composition of VLDL, LDL and HDL in subjects with PD compared to a control group; 2) to analyze the activity of plasma lipid transfer proteins and LPS plasma levels in the same groups of subjects; III) finally, to investigate the correlations between the analyzed parameters.

Subjects and method Twenty patients with PD and twenty healthy controls were recruited for the study. Fasting blood samples were taken for routine laboratory analysis and for the separation of EDTA plasma. Plasma samples stored at -80°C until were used for lipoprotein isolation and analysis and for the measurement of lipid transfer protein and LPS levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's patients

Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria

Patients not treated

Intervention Type OTHER

Control group

Subject matched for sex, age and BMI

Patients not treated

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients not treated

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Parkinson disease in agreement with UK Brain Bank
* Farmacological treatment with L-Dopa and/or dopaminergic agonist or diagnosis de novo
* BMI 18.5 - 29.9 kg/m\^2
* Informed consent signature

* Absence of major disease
* BMI 18.5 - 29.9 kg/m\^2
* Informed consent signature

Exclusion Criteria

* Presence of type 1 and type 2 diabetes mellitus
* Presence of major chronic diseases of the digestive tract.
* Pregnancy in progress
* Subjects subjected to antihypertensive therapies or statins or with drugs that can change metabolic status and insulin sensitivity (e.g. chronic oral steroid therapy)
* Subjects affected by endocrine pathologies (e.g. Cushing disease, uncontrolled thyroid disease)
* Presence of known renal insufficiency or creatinine levels greater than 1.8 mg/dl
* Presence of chronic liver disease or ALT and AST levels exceeding two standard deviations from normal levels
* Presence of malignant disease
* Alcohol or drug abuse
* Major psychiatric disorders
* Subjects dedicated to intense and agonistic physical activity.

Control group

* Presence of type 1 and type 2 diabetes mellitus
* Presence of major chronic diseases of the digestive tract.
* Pregnancy in progress
* Subjects subjected to antihypertensive therapies or statins or with drugs that can change metabolic status and insulin sensitivity (e.g. chronic oral steroid therapy)
* Subjects affected by endocrine pathologies (e.g. Cushing disease, uncontrolled thyroid disease)
* Presence of known renal insufficiency or creatinine levels greater than 1.8 mg/dl
* Presence of chronic liver disease or ALT and AST levels exceeding two standard deviations from normal levels
* Presence of malignant disease
* Alcohol or drug abuse
* Major psychiatric disorders
* Subjects dedicated to intense and agonistic physical activity.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes